Clinical Outcomes In Endocrine Disease
Posted Date: Jun 11, 2019
- Investigator: Tammy Holm
- Specialties: Cancer, Endocrinology, Head and Neck Cancer, Oncology, Otolaryngology, Surgical Oncology, Thyroid Cancer
- Type of Study: Observational/Survey
The incidence of thyroid, parathyroid, and adrenal neoplasms (surgical endocrine diseases) has been rising dramatically the past two decades. In large part, thyroid neoplasms are the major driver of this trend. In the US alone, thyroid cancer is the 6th most common cancer in women. There are estimated to be over 52,000 new cases in 2019 with over 800,000 survivors in the US alone. While the incidence of all types of thyroid cancer appears to be rising, well-differentiated thyroid cancer accounts for the vast majority (90%) of all cases. Given the relatively indolent nature of well-differentiated thyroid cancer, survivorship care must be a priority. Moreover, many thyroid tumors that are discovered are managed as putatively benign disease; thus understanding of long term clinical outcomes are critical to developing optimal treatment protocols for these patients. Similarly, most patients with parathyroid and adrenal neoplasms have benign disease with high overall and disease specific survival rates. Therefore, the study of long-term clinical outcomes of patients managed for parathyroid and adrenal tumors is necessary to optimize survivorship.
Thyroid, Parathyroid, Adrenal
For More Information: